Dermavant Sciences

Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. The company’s lead product candidate is Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent topical cream that is in Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Its product candidates in Phase I clinical trials include Cerdulatinib (DMVT-505), a dual inhibitor of the Janus kinase and spleen tyrosine kinase pathways for the treatment of vitiligo, as well as other inflammatory skin conditions, such as atopic dermatitis; and Oxybutynin/Pilocarpine (DMVT-504), an investigational oral therapy for the treatment of primary focal hyperhidrosis.

Employee Rating

4.9More
TypeSubsidiary
Parent CompanyRoivant Sciences
HQLong Beach, CA, US
Founded2016
Websitedermavant.com
Cybersecurity ratingAMore
Dermavant Sciences was founded in 2016 and is headquartered in Long Beach, CA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Dermavant Sciences

Todd Zavodnick

Todd Zavodnick

Chief Executive Officer and Director
Frank Torti

Frank Torti

Chairman
David Rubenstein

David Rubenstein

Chief Scientific Officer
Chris Chapman

Chris Chapman

Chief Commercial Officer
Philip M Brown

Philip M Brown

Chief Medical Officer
Michael Swartzburg

Michael Swartzburg

Chief Financial Officer
Show more

Dermavant Sciences Office Locations

Dermavant Sciences has offices in Long Beach, Durham, Morrisville, New York and in 2 other locations
Long Beach, CA, US (HQ)
3780 Kilroy Airport Way #250
Durham, NC, US
359 Blackwell St #240
Morrisville, NC, US
3300 Paramount Pkwy #150
New York, NY, US
320 W 37th St 5th floor
Phoenix, AZ, US
2398 E Camelback Rd #1060
Basel, CH
Viaduktstrasse 8
Show all (6)

Dermavant Sciences Financials and Metrics

Summary Metrics

Founding Date

2016

Total Funding

$200 m

Investors

In total, Dermavant Sciences had raised $200 m. Dermavant Sciences is a subsidiary of Roivant Sciences

Dermavant Sciences Revenue

USDFY, 2018FY, 2019

General and administrative expense

4.7m21.0m

R&D expense

37.4m252.3m

Operating expense total

42.1m273.2m

Pre tax profit

(42.4m)(255.2m)
USDFY, 2018FY, 2019

Cash

17.3m8.7m

Current Assets

17.5m13.8m

PP&E

28.3k1.4m

Total Assets

17.5m18.1m
USDFY, 2018FY, 2019

Net Income

(42.7m)(255.3m)

Depreciation and Amortization

10.4k139.5k

Accounts Payable

1.5m961.6k

Cash From Operating Activities

(35.3m)(257.7m)
USDFY, 2018

Financial Leverage

2 x
Show all financial metrics

Dermavant Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Dermavant Holdings Limited
Dermavant Sciences GmbH

Dermavant Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Dermavant Sciences Online and Social Media Presence

Embed Graph

Dermavant Sciences Blogs

Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress

– 58.2% of patients who entered the study with a PGA score ≥2 achieved a PGA score of 0 or 1 – Long-term use of tapinarof cream provided improved and durable effects for up to 52 weeks and demonstrated a remittive effect with a median duration of four months for patients entering with a PGA […]

Dermavant to Present New Data on Phase 3 PSOARING Program at 30th EADV Virtual Congress

– Data from tapinarof long-term extension study for the treatment of plaque psoriasis in adults selected for late-breaking oral presentation LONG BEACH, Calif., and BASEL, Switzerland, September 23, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and comme…

Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis

LONG BEACH, Calif., and BASEL, Switzerland, September 9, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that the first patient has been dosed in a Phase 3, double-blind, ve…

Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis

– Psoriasis Impacts Approximately 8 Million Americans and 125 Million People Worldwide – NDA Is Supported by Positive Data From the Phase 3 PSOARING 1 and PSOARING 2 Pivotal Efficacy Trials and Interim Results From the PSOARING 3 Long-Term Safety Study – FDA PDUFA Action Expected in Q2 2022 LONG BEA…

Dermavant Announces $200 Million of Financing

– Dermavant to Receive $160 Million from Revenue Interest Sale Upon FDA Approval of Tapinarof, Participants Include Marathon Asset Management and NovaQuest Capital Management – Proceeds to be Used to Fund All Milestone Payments Associated with Approval and Launch of Tapinarof for Treatment of Psoria…

Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis

– NDA is supported by positive data from the Phase 3 PSOARING 1 and PSOARING 2 pivotal efficacy trials and interim results from the PSOARING 3 long-term safety study LONG BEACH, Calif., and BASEL, Switzerland, June 3, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to d…
Show more

Dermavant Sciences Frequently Asked Questions

  • When was Dermavant Sciences founded?

    Dermavant Sciences was founded in 2016.

  • Who are Dermavant Sciences key executives?

    Dermavant Sciences's key executives are Todd Zavodnick, Frank Torti and David Rubenstein.

  • How many employees does Dermavant Sciences have?

    Dermavant Sciences has 74 employees.

  • Who are Dermavant Sciences competitors?

    Competitors of Dermavant Sciences include Amarna Therapeutics, Biosearch Life and ANI Pharmaceuticals.

  • Where is Dermavant Sciences headquarters?

    Dermavant Sciences headquarters is located at 3780 Kilroy Airport Way #250, Long Beach.

  • Where are Dermavant Sciences offices?

    Dermavant Sciences has offices in Long Beach, Durham, Morrisville, New York and in 2 other locations.

  • How many offices does Dermavant Sciences have?

    Dermavant Sciences has 6 offices.